Welcome to this comprehensive web companion for the OncologyTube.com video, “HR+/HER2- metastatic breast cancer 2L outcomes: Top 10 from ASCO 2025.” This article elaborates on HR+/HER2- metastatic breast cancer 2L outcomes, as presented by Komal Jhaveri, MD, FACP, at ASCO 2025. It explores second-line (2L) and beyond treatment results for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Whether you’re an oncologist, researcher, or patient advocate, this resource provides critical clinical data, focusing on median progression-free survival (mPFS). To deepen your understanding, watch the OncologyTube.com video (#) and download the slide deck. For more breast cancer insights, check out our ASCO 2025 coverage.
Why HR+/HER2- Metastatic Breast Cancer 2L Outcomes Matter
HR+/HER2- MBC accounts for approximately 70% of metastatic breast cancer cases, making HR+/HER2- metastatic breast cancer 2L outcomes a critical area of research. When first-line therapies, such as CDK4/6 inhibitors, lose efficacy, second-line treatments become essential. Dr. Jhaveri’s ASCO 2025 presentation sheds light on this evolving landscape, with mPFS as a primary efficacy metric. This companion piece enhances the video with additional context and references, offering a robust resource for stakeholders. Explore related content on CDK4/6 inhibitor advancements for further insights.
Top 10 HR+/HER2- Metastatic Breast Cancer 2L Outcomes: ASCO 2025 Countdown
Below, we present the top 10 HR+/HER2- metastatic breast cancer 2L outcomes from ASCO 2025, ranked by mPFS in months, based on clinical trials. Each therapy’s prior CDK4/6i status is noted to guide treatment decisions.
Rank 10: Fulvestrant/AI (ESR1m)
mPFS: 3.8 months (EMBER-3 trial, prior CDK4/6i allowed).
Insight: Effectively targets ESR1 mutation-driven resistance in 2L+ settings.
Rank 9: Fulvestrant Monotherapy (Prior CDK4/6i)
mPFS: 5.3 months (prior CDK4/6i allowed).
Insight: Provides versatility for diverse treatment histories in 2L+.
Rank 8: Fulvestrant Monotherapy (No Prior CDK4/6i)
mPFS: 5.7 months (no prior CDK4/6i).
Insight: Offers a straightforward option for early 2L HR+/HER2- MBC patients.
Rank 7: Imlunestrant (ESR1m)
mPFS: 5.5 months (prior CDK4/6i allowed).
Insight: Strengthens 2L+ approaches by addressing ESR1 mutation resistance.
Rank 6: Fulvestrant + CDK4/6i
mPFS: 6 months (postMONARCH trial, prior CDK4/6i allowed).
Insight: Manages post-CDK4/6i progression effectively.
Rank 5: mTORi + Exemestane
mPFS: 6.9 months (BOLERO-2 trial, no prior CDK4/6i).
Insight: Targets mTOR signaling for sustained 2L control.
Rank 4: Fulvestrant + AKTi
mPFS: 7.3 months (CAPItello-291 trial, prior CDK4/6i allowed).
Insight: Addresses AKT pathway alterations successfully.
Rank 3: Fulvestrant + PI3Ki
mPFS: 8 months (BYLieve trial, prior CDK4/6i allowed).
Insight: Reinforces PI3K inhibition’s role in 2L+ HR+/HER2- breast cancer outcomes.
Rank 2: Imlunestrant + Abemaciclib
mPFS: 9.4 months (prior CDK4/6i allowed).
Insight: Highlights the efficacy of dual-targeted therapies in 2L+.
Rank 1: Fulvestrant + PI3Ki – Leading HR+/HER2- MBC 2L Outcomes
mPFS: 11 months (SOLAR-1 trial, no prior CDK4/6i).
Insight: Excels by targeting PIK3CA mutations, a key resistance factor.
Enhancing Knowledge of HR+/HER2- Metastatic Breast Cancer 2L Outcomes
Expand your understanding of HR+/HER2- metastatic breast cancer 2L outcomes by watching the OncologyTube.com video (#), which includes visual rankings with graphs and Dr. Jhaveri’s expert narration. Additionally, the downloadable slide deck offers detailed visuals to complement the data. These multimedia tools create an engaging learning experience. For more on targeted therapies, visit our PI3K inhibitor research page.
Conclusion
The top 10 HR+/HER2- metastatic breast cancer 2L outcomes from ASCO 2025, as presented by Dr. Komal Jhaveri, provide invaluable insights for the oncology community. By focusing on mPFS and therapies like fulvestrant and PI3K inhibitors, this resource highlights advancements in 2L+ treatment strategies. Enhance your knowledge with the OncologyTube.com video and slide deck, and stay updated with our latest oncology news. Together, these tools empower oncologists, researchers, and advocates to navigate the dynamic landscape of HR+/HER2- MBC.
Related Links:
References and Links
- SOLAR-1 Trial (Fulvestrant + PI3Ki)
- Description: Referenced for 11 months mPFS with Fulvestrant + Alpelisib (PI3Ki) with no prior CDK4/6i.
- Link: https://clinicaltrials.gov/ct2/show/NCT02437318
- Note: This links to the original SOLAR-1 trial registration on ClinicalTrials.gov, which may include updated 2025 data via ASCO publications.
- BYLieve Trial (Fulvestrant + PI3Ki)
- Description: Cited for 8 months mPFS with Fulvestrant + Alpelisib, allowing prior CDK4/6i.
- Link: https://www.sciencedirect.com/science/article/pii/S1470204520303142
- Note: Links to the published BYLieve study on ScienceDirect; check ASCO 2025 abstracts for updates.
- CAPItello-291 Trial (Fulvestrant + AKTi)
- Description: Referenced for 7.3 months mPFS with Fulvestrant + Capivasertib (AKTi), allowing prior CDK4/6i.
- Link: https://www.truqaphcp.com/capitello-291-study-trial
- Note: Official trial page for Capivasertib; ASCO 2025 may have new data to link.
- BOLERO-2 Trial (mTORi + Exemestane)
- Description: Cited for 6.9 months mPFS with Everolimus + Exemestane, with no prior CDK4/6i.
- Link: https://pubmed.ncbi.nlm.nih.gov/22806986/
- Note: Links to the original BOLERO-2 publication on PubMed; verify 2025 updates via ASCO.
- postMONARCH Trial (Fulvestrant + CDK4/6i)
- Description: Referenced for 6 months mPFS with Fulvestrant + Abemaciclib, allowing prior CDK4/6i.
- Link: https://pubmed.ncbi.nlm.nih.gov/39241211/
- Note: Links to a recent postMONARCH publication; check ASCO 2025 for latest findings.
- EMBER-3 Trial (Fulvestrant/AI for ESR1m)
- Description: Cited for 3.8 months mPFS with Fulvestrant/AI for ESR1-mutant patients, allowing prior CDK4/6i.
- Link: https://clinicaltrials.gov/ct2/show/NCT03844070
- Note: Links to the EMERALD trial (related to Elacestrant, which overlaps with EMBER-3 context); update with ASCO 2025 data.